• Simran Ganeriwal, Gabriele Alves Dos Anjos, Mary Schleicher, Maxwell A Hockstein, Adriano R Tonelli, Abhijit Duggal, and Matthew T Siuba.
• Department of Internal Medicine, Community Care Institute, Cleveland Clinic, Cleveland, OH, USA.
• Crit Care. 2023 Mar 12; 27 (1): 104104.

ObjectiveTo summarize knowledge and identify gaps in evidence regarding treatment of right ventricular dysfunction (RVD) in acute respiratory distress syndrome (ARDS).Data SourcesWe conducted a comprehensive search of MEDLINE, Embase, CINAHL, Web of Science, and the Cochrane Central Register of Controlled Trials.Study SelectionStudies were included if they reported effects of treatments on right ventricular function, whether or not the intent was to modify right ventricular function.Data ExtractionData extraction was performed independently and in duplicate by two authors. Data items included the study design, patient population, type of intervention, comparison group, and RV-specific outcomes.Data SynthesisOf 1,430 studies screened, 51 studies reporting on 1,526 patients were included. By frequency, the included studies examined the following interventions: ventilator settings (29.4%), inhaled medications (33.3%), extracorporeal life support (13.7%), intravenous or oral medications (13.7%), and prone positioning (9.8%). The majority of the studies were non-randomized experimental studies (53%), with the next most common being case reports (16%). Only 5.9% of studies were RCTs. In total, 27% of studies were conducted with the goal of modifying RV function.ConclusionsGiven the prevalence of RVD in ARDS and its association with mortality, the dearth of research on this topic is concerning. This review highlights the need for prospective trials aimed at treating RV dysfunction in ARDS.© 2023. The Author(s).

12 keywords...

hide…